Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Cytokinetics (CYTK) over the last 15 years, with Sep 2025 value amounting to $9.4 million.

  • Cytokinetics' Capital Expenditures rose 1234.38% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 659.49%. This contributed to the annual value of $3.9 million for FY2024, which is 175.85% up from last year.
  • Cytokinetics' Capital Expenditures amounted to $9.4 million in Q3 2025, which was up 125.67% from $4.1 million recorded in Q2 2025.
  • Cytokinetics' Capital Expenditures' 5-year high stood at $17.8 million during Q4 2021, with a 5-year trough of $77,000 in Q4 2023.
  • For the 3-year period, Cytokinetics' Capital Expenditures averaged around $2.2 million, with its median value being $701,000 (2024).
  • In the last 5 years, Cytokinetics' Capital Expenditures plummeted by 97.60% in 2023 and then soared by 2,474.53% in 2025.
  • Over the past 5 years, Cytokinetics' Capital Expenditures (Quarterly) stood at $17.8 million in 2021, then slumped by 81.95% to $3.2 million in 2022, then plummeted by 97.60% to $77,000 in 2023, then soared by 1,575.32% to $1.3 million in 2024, then soared by 1,234.38% to $9.4 million in 2025.
  • Its Capital Expenditures was $9.4 million in Q3 2025, compared to $4.1 million in Q2 2025 and $5.7 million in Q1 2025.